A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation

RecruitingOBSERVATIONAL
Enrollment

328

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
HR+HER2- Advanced Breast Cancer
Trial Locations (20)

150054

RECRUITING

Novartis Investigative Site, Yaroslavl

163045

RECRUITING

Novartis Investigative Site, Arkhangelsk

170008

RECRUITING

Novartis Investigative Site, Tver'

194291

RECRUITING

Novartis Investigative Site, Saint Petersburg

197758

RECRUITING

Novartis Investigative Site, Saint Petersburg

241028

RECRUITING

Novartis Investigative Site, Bryansk

249036

RECRUITING

Novartis Investigative Site, Obninsk

344006

RECRUITING

Novartis Investigative Site, Rostov-on-Don

392000

RECRUITING

Novartis Investigative Site, Tambov

450054

RECRUITING

Novartis Investigative Site, Ufa

454080

RECRUITING

Novartis Investigative Site, Chelyabinsk

610021

RECRUITING

Novartis Investigative Site, Kirov

614066

RECRUITING

Novartis Investigative Site, Perm

620036

RECRUITING

Novartis Investigative Site, Yekaterinburg

628012

RECRUITING

Novartis Investigative Site, Khanty-Mansiysk

650036

RECRUITING

Novartis Investigative Site, Kemerovo

656045

RECRUITING

Novartis Investigative Site, Barnaul

660022

RECRUITING

Novartis Investigative Site, Krasnoyarsk

664035

RECRUITING

Novartis Investigative Site, Irkutsk

680042

RECRUITING

Novartis Investigative Site, Khabarovsk

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY